September 4, 2024
Archer CGP research assays now enable homologous recombination deficiency (HRD) assessment for identification of key biomarkers critical for cancer research CORALVILLE, Iowa — With a history of driving innovation and collaboration in next generation sequencing (NGS), Integrated DNA Technologies is expanding its Archer portfolio of comprehensive genomic profiling (CGP) solutions to include homologous recombination deficiency [...]
VedaBio Appoints Dr. G. Brett Robb as Senior Scientific Director and Head of CRISPR Science
September 4, 2024
Accomplished R&D Leader and CRISPR Tools Expert Joins VedaBio to Drive Platform Expansion and Industrialization SAN DIEGO -- VedaBio, a biotechnology company leading a paradigm shift in molecular detection, today announced the appointment of G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science. With over 16 years of experience in life [...]
September 4, 2024
DKSH has formed an exclusive partnership with Hygiena®, a global leader in food safety and health diagnostics solutions. DKSH will leverage its market expansion services to enhance Hygiena’s presence in Cambodia, Laos and Myanmar. Camarillo, California – DKSH Business Unit Technology has announced a new, exclusive partnership with Hygiena, a prominent provider in rapid microbial detection, [...]
POROLUX™ Revo series is eXpanding!
September 4, 2024
We’re excited to introduce the newest member of our POROLUX™ Revo series—the POROLUX™ Revo X! The Revo X is tailored for applications with relatively large pores, while demanding the high precision and ease of use that you expect from our POROLUX™ Revo. With the smallest detectable pore size of 80 nm (max. pressure 8 bar), [...]
Revio to Power Research in Male Infertility and Rare Disease at Münster University Hospital
September 4, 2024
Highly Accurate Long-Read Sequencing Data from Revio will Support Germany’s National Genome Initiative and Provide Data to the International Male Infertility Consortium MENLO PARK, Calif. -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly [...]
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
September 4, 2024
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass. -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth [...]
September 4, 2024
BRANFORD, Conn. -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™ (“NGPS”) into their platform for developing novel gene therapies with improved targeting capabilities. Liberate [...]
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
September 4, 2024
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications Dublin, Ireland, and Cheshire, UK: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent [...]
LumaCyte Unveils Predictive CAR T Donor Analytics to Revolutionize Cell Therapy Manufacturing
September 4, 2024
CHARLOTTESVILLE, Va. -- LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for predictive CAR T donor analytics. Leveraging its novel Laser Force Cytology™ (LFC™) technology and Radiance® instrument, LumaCyte uncovers deep data insights into highly variable and complex patient and donor cellular starting [...]
September 4, 2024
Grant will facilitate HPTLS platform development for additional biomanufacturing areas that face critical challenges, including upstream bioprocessing and in-line/in-situ applications Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, has been awarded a $2 million Small Business Innovation Research (SBIR) Direct Phase II Grant from the National Institutes of Health (NIH). This [...]

